Corifollitropin alfa: a new recombinant gonadotropin for the treatment of infertility

摘要

Corifollitropin alfa (Elonva~R), a novel recombinant glycoprotein designed as a sustained follicle stimulant, is indicated for the development of multiple follicles in patients undergoing controlled ovarian stimulation (COS) in combination with a gonadotropin releasing hormone (GnRH) antagonist prior to in vitro fertilization (IVF) or intracytoplasmic sperm injection (ICSI). A single subcutaneous injection of corifollitropin alfa is able to initiate and sustain multiple follicular development during the first 7 days of ovarian stimulation, and thus replaces a whole week of daily follicular stimulating hormone (FSH) injections. This paper profiles the development of corifollitropin alfa and reviews accumulating clinical data which supports its indicated use as a safe and efficacious therapy that promises to greatly reduce the burden of IVF in patients with infertility.